Stereoselective Synthesis of Hydroxylated Indolizidines via (–)-Sparteine-Mediated Kinetic Resolution Coupled with Intramolecular Carbolithiation

Michael J. Woltering, Roland Fröhlich⁺, Birgit Wibbeling⁺, Dieter Hoppe^{*}

Organisch-Chemisches Institut der Universität Münster, Corrensstr. 40, D-48149 Münster, Germany

Fax +49(251) 833-9772

Received 6 April 1998

Abstract: Enantioenriched 1-oxy-2-benzyl-substituted indolizidines with functionalized side chains were easily prepared from racemic 2-(carbamoyloxy)methyl-*N*-cinnamylpiperidine by (–)-sparteine-mediated one-step kinetic resolution and intramolecular carbolithiation.

Hydroxylated indolizidine alkaloids such as lentiginosine, castanospermine, swainsonine, and related compounds¹ demonstrate a high pharmacological potential as specific inhibitors of glycosidase and glycoprotein processing² as well as anticancer, antiviral, antiretroviral, and immunoregulatory agents.³ Thus, the development of methods for the synthesis of enantioenriched hydroxylated indolizidines has become important for the discovery of new pharmacologically interesting heterocyclic compounds and attracted great attention during the last decade.⁴ Among a great diversity of synthetic methods, intramolecular cyclocarbometallation⁵ reactions have been applied for the construction of five- and six-membered nitrogen heterocycles,⁶ including one example utilizing an enantioenriched lithiated carbanion.⁷ We wish to report herein a short but efficient stereoselective approach to hydroxylated indolizidines via the (-)-sparteine-mediated enantioselective deprotonation.8 As we previously reported, the and intramolecular enantioselective deprotonation 5-exo-trig

cyclocarbolithiation of 6-phenyl-5-hexenyl carbamates 1 turned out to be a useful tool for generating enantiomerically pure 2-substituted cyclopentanol derivatives 2 (Scheme 1).⁹





In order to transfer this method to the synthesis of bicyclic heterocycles, we supposed that indolizidines can be synthesized by stereoselective intramolecular carbolithiation. The diastereoselectivity of the deprotonation and substitution of β -alkyl and β -amino-substituted alkyl carbamates as well as the (–)-sparteine-mediated kinetic resolution of these compounds have been investigated extensively in our group.¹⁰ Therefore, the (–)-sparteine mediated deprotonation even of racemic 2-(carbamoyloxy)methyl-*N*-cinnamyl-piperidine *rac-4* seemed to be an elegant method to obtain enantioenriched indolizidines via kinetic resolution and subsequent diastereoselective anionic *5-exo-trig* cyclization by a one-step procedure. The precursor *rac-4* was easily prepared by a two-step sequence (Scheme 2).



Scheme 2. a) 1.5 eq. K_2CO_3 , toluene, reflux, 2 h, then 1.05 eq. cinnamyl bromide, reflux, 20 h; b) 1.5 eq. NaH, THF, r.t., 1 h, then 1.5 eq. *Cby*Cl, reflux, 24 h

Compound *rac-4* was treated with *sec*-butyllithium in the presence of (-)-sparteine in diethyl ether at -78 °C, the reaction mixture was stirred at this temperature for 8 to 32 h, and methanol was subsequently added. In order to improve the efficiency of the kinetic resolution, different reaction conditions were checked (Scheme 3, Table 1).



Scheme 3. a) (–)-sparteine (3), s-BuLi, Et₂O, – 78 °C, 8 – 32 h. b) MeOH, – 78 °C \rightarrow r.t.

Table 1. Conditions for the kinetic resolution and resulting selectivities

Entry	Equiv.	Equiv.	Time	d.r.	Yield	Ee	Yield 4
No.	(-)-spart. (3)	s-BuLi	[h]	(7:8) ^[a]	7 [%]	7 ^[b]	[%]
						[%]	
1	-	1.00	20	96 : 4 ^[c]	30	-	-
2	1.00	0.91	8	91:9	54	67	23
3	1.00	0.97	22	92:8	42	91	25
4	1.00	0.91	32	92:8	45	89	22
5	0.80	0.75	22	98 : 2 ^[d]	34	95	46 ^[e,f]

[a] Determined by gas chromatography. [b] Determined by ¹H NMR shift experiments with the acetates. [c] Racemates. [d] Optical rotation of **7**: $[\alpha]^{20}_{D} = +3.9$ (c = 1.09, CH₂Cl₂). [e] The *ee* of 63 % was determined by ¹H NMR after decarbamoylation and formation of the Mosher ester with (-)-(*S*)- α -methoxy- α -(trifluoromethyl)-phenylacetic acid. [f] Optical rotation of recovered **4**: $[\alpha]^{20}_{D} = -23.2$ (c = 1.13, CH₂Cl₂).

The 5-*exo-trig* cyclization reaction led to the *trans*-fused five-membered heterocycles **7** and **8** with excellent diastereoselectivity. The *cis*-fused heterocycles could not be detected in any case. The anion emerging from the matched pair as well as the anion derived from the mismatched pair underwent *trans*-selective 5-*exo-trig* cyclization.¹¹ Therefore, the two diastereomers resulted from incomplete differentiation within the deprotonation step and not within the cyclization step.

As Table 1 shows, the use of 0.80 eq. of (–)-sparteine (**3**), 0.75 eq. of *s*-BuLi and a reaction time of 22 h (Entry 5) resulted in a yield of 34 % of indolizidine **7** (based on *rac-4*) with high diastereoselectivity (**7**:**8** = 98:2) and an enantiomeric excess of 95 %.¹² Under these conditions, (*S*)-(–)-**4** was recovered with 46 % yield and 63 % *ee*.

These optimized conditions were used for trapping the intermediate benzylic anion with different electrophiles. Thus, further functionalization of the side chain and the generation of one more 798



Scheme 4. a) 0.80 eq. (-)-sparteine, 0.75 eq. s-BuLi, Et₂O, -78 °C; b) 22 h, 5-*exo-trig*-cyclization; c) El-X, -78 °C \rightarrow r.t.

The reactions with all tin and silicon electrophiles yielded mixtures of **9** and **10** in different ratios which could be separated easily by flash chromatography (silica gel, petroleum ether/ethyl acetate/ triethylamine). With CO₂, after converting the crude acid to the methyl ester **9f** with diazomethane, one single diastereomer with the configuration [1*S*,2*R*,8a*R*,2(1*S*)] could be detected. Table 2 shows the results of benzylic substitution depending on the electrophile.

 Table 2. Compounds 9 and 10 obtained by trapping the intermediate benzyllithium

El-X	Comp. No. ^[a]	<i>d.r.</i> 9 : 10	Yield 9+10 [%]	Yield 4 [%]	$[\alpha]_{\rm D}^{20}$ (9) ^[b]	$[\alpha]_{\rm D}^{20}$ (10) ^[b]
D-OAc	9a/10a	25 : 75	40	31	-	-
Bu ₃ Sn-Cl	9b/10b	11:89	33	64	- 54.4	+ 56.1
Me ₃ Sn-Cl	9c/10c	25 : 75	31	67	-42.4	+ 38.8
Me ₃ Si-Cl	9d/10d	45 : 55	29	61	- 24.7	+ 3.9
Me ₂ PhSi-Cl	9e/10e	75 : 25	32	63	- 30.6	+ 12.6
CO ₂ Me	9f	> 95 : 5	30	51	+ 34.6	-

[a] All compounds gave satisfactory elemental analyses (C \pm 0.40; H \pm 0.23; N \pm 0.42) or correct high-resolution mass spectra. [b] Optical rotations measured in CH₂Cl₂ (c = 0.3 - 1.2)

The diastereomers **9** and **10** have the same relative configuration at C1, C2, and C8a, and must differ in the side chain. The absolute configuration of the minor diastereomer $9d^{14,15}$ (Figure 1) and the relative configuration of the racemic ester $9f^{15,16}$ (Figure 2) were determined by X-ray crystal structure analysis. The relative configuration of 9b/10b, 9c/10c, and 9e/10e was determined by correlation of ¹H NMR data of the remaining proton at C1 with the data of 9d/10d (Table 3).

The high diastereoselectivity found for the benzylic substitution of related carbocycles⁹ is not operating in the indolizidine system. Obviously, the interconversion of the epimeric ion pairs **5** (**R**) and **5** (**S**) proceeds with a rate comparable to the rate of the substitution step, the latter differing significantly in both reaction pathways for each electrophile. We assume, with exception of the deuterolysis,¹⁷ inversion of configuration in the substitution step. Inversion has been found for all silylations, stannylations, alkylations, and several carboxylations of α -hetero-substituted benzyllithium compounds.^{18,19} Under these assumptions, the major products **10a** and **9f**, formed in very rapid deuterolysis or carboxylation, arise from the ion pair **5** (**R**), which is expected to be primarily formed in the intramolecular *syn*-addition. In contrast, the major products **10b-d** emerge from the ion pair **5**(**S**), being



Figure 1. X- ray crystal structure of 9d



Figure 2. X-ray crystal structure of 9f

 Table 3. ¹H NMR data of the remaining proton at C1 of products 9 and 10

Compd.		9			10	
No.	δ(H1)[ppm]	${}^{3}J_{1,2}$ [Hz]	³ J _{1,8a} [Hz]	δ(H1) [ppm]	${}^{3}J_{1,2}$ [Hz]	³ J _{1,8a} [Hz]
9a/10a	4.71	4.79	7.88	4.71	4.79	7.88
9b/10b	4.68	4.29	7.65	4.71	3.33	6.18
9c/10c	4.70	4.29	7.62	4.78	3.59	6.68
9ď/10d	4.74	4.53	7.62	4.90	4.29	6.66
9e/10e	4.65	4.29	7.62	4.81	4.05	6.42
9f	4.73	5.24	7.88	-	-	-

in equilibrium with 5(R). Presumably, a dynamic kinetic resolution^{8b,18d,20} is operating in the substitution reaction with slower electrophiles, such as silicon and tin chlorides.

The method described here allows a short but efficient approach to enantioenriched 1,2-disubstituted indolizidines establishing up to four stereogenic centers under the action of the recoverable auxiliary (–)-sparteine. The key steps are a kinetic resolution and a stereospecific and, as well, diastereoselective anionic cyclization starting from readily available racemic material. Moreover, further functionalization of the side chain can be established by trapping with electrophiles. The enantiomers *ent-5*, *ent-9* and *ent-10* are accessible from the recovered (S)-(–)-4.

Acknowledgement:

This work was supported by the Deutsche Forschungsgemeinschaft and the Fonds der Chemischen Industrie.

References and Notes:

- ⁺ X-ray crystal structure determination.
- For reviews concerning lentiginosine, castanospermine, swainsonine, see: a) Brown Jr., K. S.; Trigo, J. R. *The Alkaloids, Chemistry and Pharmacology* 1995, *47*, 227. b) Michael, J. P. *Nat. Prod. Rep.* 1994, *11*, 17; 1994, *11*, 639; 1995, *12*, 535; 1997, *14*, 21; 1997, *14*, 619.
- a) Elbein, A. D.; Molyneux, R. J. in Alkaloids: Chemical and Biological Perspectives; Pelletier, S. W. (Ed.); Wiley: New York, 1987; Vol. 5, Chapter 1, pp 1 – 54. b) Papandreou, G.; Tong, M. K.; Ganem, G. J. Am. Chem. Soc. 1993, 115, 11682. c) Legler, G.; Korth, A.; Berger, A.; Ekhart, C.; Gradnig, G.; Stütz, A. E. Carbohydr. Res. 1993, 250, 67. d) Kang, M. S.; Bowlin, T. L.; Vijay, I. K.; Sunkara, S. P. Carbohydr. Res. 1993, 248, 327. e) Pastuszak, I.; Molyneux, R. I.; James, L. F.; Elbein, A. D Biochemistry 1990, 29, 1886.
- a) Elbein, A. D. Annu. Rev. Biochem. 1987, 56, 497. b) Sunkara, P. S.; Bowlin, T. L.; Liu, P. S.; Sjoerdsma, A. Biochem. Biophys. Res. Commun. 1987, 148, 206. c) Gruters, R. A.; Neefjes, J. J.; Tersmette, M.; de Goede, R. E. Y.; Tulp, A.; Huisman, H. G.; Miedema, F.; Ploegh, H. L. Nature 1987, 330, 74. d) Humphries, M. J.; Matsumoto, K.; White, S. L.; Olden, K. Cancer Res. 1986, 46, 5215. e) Dennis, J. W. Cancer Res. 1986, 46, 5131.
- a) Brandi, A.; Cicchi, S.; Cordedo, F. M.; Frignoli, R.; Goti, A.; Picasso, S.; Vogel, P. J. Org. Chem. 1995, 60, 6806. b) Cordero, F. M.; Cicchi, S.; Goti, A.; Brandi, A. Tetrahedron Lett. 1994, 35, 949. c) Zhou, W.-S.; Xie, W.-G.; Lu, Z.-H.; Pan, X.-F. Tetrahedron Lett. 1995, 36, 1291. d) Yoda, H.; Kawaguchi, M.; Takanabe, K. Synlett 1998, 137. e) Yoda, H.; Nakajiama, T.; Takanabe, K. Synlett 1997, 911. f) Gmeiner, P.; Junge, D. J. Org. Chem. 1995, 60, 3910. g) Cuny, G. D.; Buchwald, S. L. Synlett 1995, 519. h) Sato, Y.; Nukui, S.; Sodeoka, M.; Shibasaki, M. Tetrahedron 1994, 50, 371.
- 5. For cyclocarbolithiation see: Bailey, W. F.; Gavaskar, K. V. *Tetrahedron* **1994**, *50*, 5957.
- a) Zhang, D.; Liebeskind, L. S. J. Org. Chem. 1996, 61, 2594.
 b) Bailey, W. F.; Jiang, X.-L. J. Org. Chem. 1996, 61, 2596.
 c) Lorthois, E.; Marek, I.; Normant, J.-F. J. Org. Chem. 1998, 63, 566.
 d) Oppolzer, W.; Kuo, D. L.; Hutzinger, M. W.; Léger, R.; Durand, J.-O.; Leslie, C. Tetrahedron Lett. 1997, 38, 6213.
- Coldham, I.; Hufton, R.; Snowden, D. J. J. Am. Chem. Soc. 1996, 118, 5322.
- a) Hoppe, D.; Hense, T. Angew. Chem. 1997, 109, 2376; Angew. Chem. Int. Ed. Engl. 1997, 36, 2282. b) Beak, P.; Basu, A.; Gallagher, D. J.; Park, Y. S.; Thayumanavan, S. Acc. Chem. Res. 1996, 29, 552.
- a) Woltering, M. J.; Fröhlich, R.; Hoppe, D. Angew. Chem. 1997, 109, 1804; Angew. Int. Ed. Engl. 1997, 36, 1764. b) Oestreich, M.; Fröhlich, R.; Hoppe, D. Tetrahedron Lett. 1998, in press.
- a) Haller, J.; Hense, T.; Hoppe, D. Synlett 1993, 726. b) Hoppe, D.; Hintze, F.; Tebben, P.; Paetow, M.; Ahrens, H.; Schwerdtfeger, J.; Sommerfeld, P.; Haller, J.; Guarnieri, W.; Kolczewski, S.; Hense, T.; Hoppe, I. Pure Appl. Chem. 1994, 66, 1479. c) Hoppe, D.; Ahrens, H.; Guarnieri, W.; Helmke, H.; Kolczewski, S. Pure

SYNLETT

 The determination of the relative configuration of 7 and 8 was established by ¹H NMR NOE experiments. We gratefully thank Dr. Klaus Bergander for the measurements at the 600 MHz NMR spectrometer.



- The enantiomeric eccess of the acetate was determined by 300 MHz ¹H NMR shift experiment using 11 mol% (+)-Eu(hfc)₃ in CDCl₃.
- 13. Typical procedure:

To a solution of racemic 2-(carbamoyloxy)methyl-Ncinnamylpiperidine (rac-4, 193 mg, 0.50 mmol) and (-)-sparteine (3, 94 mg, 0.40 mmol) in diethyl ether (3 mL) a 1.3M secbutyllithium solution in hexanes (0.375 mmol) was added at - 78 °C. The solution was stirred for 22 h at this temperature and subsequently chlorotrimethylsilane (0.13 ml, 1.0 mmol) was added. The reaction mixture was slowly warmed to rt (5 h), aq. K₂CO₃ solution (2mL) was added, the layers were separated and the aqueous layer was extracted three times with diethyl ether. The combined organic layers were dried over Na2SO4 and evaporated in vacuo. The purification of the remaining crude product by flash chromatography (silica gel, petroleum ether/EtOAc/Et₃N 10:0.5:0.15) yielded 36 mg of **10d** ($R_f = 0.50$) and 30 mg of **9d** (R_f = 0.36) [*d.r.* (9d:10d) = 45:55, 29 %) as well as 118 mg (61 %) of remaining 4.

10d: $R_f = 0.50$ (PE/EtOAc/NEt₃ 10:0.5:0.15). $[\alpha]_D^{20} = + 3.9;$ $[\alpha]^{20}_{365} = +51.4$ (c = 0.28 in CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃): $\delta = 0.00$ (s, 9H, *Si*(*C*H₃)₃); 1.46, 1.48 (s, 6H), 1.62 (s, 6H, Cby-CH₃); 1.40 - 1.64 (m, 5H), 1.79 (m, 1H), 1.90 (m, 2H, H- $5_a/6/7/8/8a$); 2.39 (dd, 1H, ${}^{3}J_{2,3a} = 9.75$ Hz, ${}^{2}J_{3a,3b} = 8.82$ Hz, H- J_a ; 2.43 (d, 1H, ${}^{3}J_{2,2(1)} = 10.98$ Hz, H-2(1)); 2.69 (m, 2H, H-2/ 3_b); 2.85 (m, 1H, H-5_b); 3.78 (s, 2H, Cby-CH₂); 4.90 (dd, 1H, ${}^{3}J_{1,8a} = 6.66$ Hz, ${}^{3}J_{1,2} = 4.29$ Hz, H-1); 7.07 – 7.28 (m, 5H, Haryl). ¹³C NMR (75 MHz, CDCl₃): $\delta = -1.4 \text{ q} (Si(CH_3)_3)$; 24.1 t, 24.2 t (C-6/7); 25.5, 25.1 q, 25.7, 26.1 q (Cby-CH₃); 29.2 t (C-8); 41.3 d (C-2(1)); 43.5 d (C-2); 52.9 t (C-5); 58.9 t (C-3); 59.7, 61.1 s (Cby-C(CH₃)₂); 70.5 d (C-8a); 76.5, 76.2 t (Cby-CH₂); 82.4 d (C-1); 96.0, 95.1 s (Cby-C(CH₃)₂); 124.7 d, 128.0 d, 128.8 d, 143.9 s (C-aryl); 152.6, 151.6 s (NC=O). IR (Film): v [cm⁻¹]: 3060 - 2780 (s, C-H); 1685 (s, NC=O); 1450, 1365. C₂₆H₄₂N₂O₃Si (458.718): Calc.: C 68.08, H 9.23, N 6.11. Found: C 68.36, H 9.46, N 6.53. 9d: $R_f = 0.36$ (PE/EtOAc/NEt₃) 10:0.5:0.15). Mp: 89 °C (*n*-hexane). $[\alpha]^{20}{}_{D} = -24.7, [\alpha]^{20}{}_{365} = -$ 109.4 (c = 0.32 in CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃): $\delta = -$ 0.05 (s, 9H, $Si(CH_3)_3$); 1.15 - 1.90 (m, 19H, Cby- CH_3 /H-6/7/8/ 8a); 2.03 (m, 1H, H-5_a); 2.38 (d, 1H, ${}^{3}J_{2,9} = 11.19$ Hz, H-2(1)); 2.65 (m, 2H, H-2/3_a); 3.01 (m, 2H, H-3_b/5_b); 3.72 (s, 2H, H-5'); 4.74 (dd, 1H, ${}^{3}J_{1,8a}$ = 7.62 Hz, ${}^{3}J_{1,2}$ = 4.53 Hz, H-1); 7.02 - 7.07 (m, 3H), 7.15 - 7.22 (m, 2H, H-aryl). ${}^{13}C$ NMR (75 MHz, CDCl₃): $\delta = -1.1$ q (Si(CH₃)₃); 24.0 t (C-7); 24.8 t (C-6); 25.4 q, 25.6, 25.9, 27.0 q (Cby-CH₃); 28.7 t (C-8); 42.1 d (C-2(1)); 43.0 d (C-2); 53.3 t (C-5); 58.8 t (C-3); 59.3, 60.3 s (Cby-C(CH₃)₂); 69.0 d (C-8a); 76.4, 76.1 t (Cby-CH2); 82.9 d (C-1); 95.7 [94.4] s (Cby $\begin{array}{l} C(CH_3)_2); \ 124.7 \ d, \ 127.6 \ d, \ 128.9 \ d, \ 142.6 \ s \ (C-aryl); \ 151.6, \\ 151.0 \ s \ (NC=O). \ IR \ (KBr): \nu \ [cm^{-1}]: \ 3050 - 2780 \ (s, \ C-H); \ 1695 \\ (s, \ NC=O); \ 1465, \ 1395, \ 1365, \ 1335. \ C_{26}H_{42}N_2O_3Si \ (458.718): \\ Calc.: C \ 68.08, H \ 9.23, N \ 6.11. \ Found: C \ 68.48, H \ 9.42, N \ 6.07. \end{array}$

- 14. X-ray crystal structure analysis of **9d**: formula $C_{26}H_{42}N_2O_3Si$, $M = 458.71, 0.30 \times 0.10 \times 0.10$ mm, a = 8.146(1), b = 16.250(2), c = 10.581(1) Å, $\beta = 104.28(1)^\circ$, V = 1357.4(3) Å³, $\rho_{calc} = 1.122$ g cm⁻¹, $\mu = 9.71$ cm⁻¹, empirical absorption correction via φ scan data (0.973 $\leq C \leq 0.999$), Z = 2, monoclinic, space group $P2_1$ (No. 4), $\lambda = 1.54178$ Å, T = 223 K, $\omega/2\theta$ scans, 6169 reflections collected (+h, $\pm k$, $\pm l$), [(sin θ)/ λ] = 0.62 Å⁻¹, 5562 independent and 4492 observed reflections [$I \geq 2 \sigma(I)$], 296 refined parameters, R = 0.043, $wR^2 = 0.105$, max. residual electron density 0.41 (-0.22) e Å⁻³, Flack parameter 0.00(3), hydrogens calculated and refined as riding atoms.
- Data sets were collected with an Enraf Nonius CAD4 diffractometer. Programs used: data reduction MolEN, structure solution SHELXS-86, structure refinement SHELXL-93, graphics SCHAKAL-92.

Crystallographic data (excluding structure factors) for the structures reported in this paper have been deposited with the number: 101328 at the Cambridge Crystallographic Data Centre as supplementary publication. Copies of the data can be obtained free of charge on application to The Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: int. code +44(1223)336-033, e-mail: deposit@ccdc.cam.ac.uk].

- 16. From a 28 mg portion of the highly enantioenriched methyl ester **9f** could be crystallized less than 2 mg of racemic material. X-ray crystal structure analysis of **9f**: formula $C_{25}H_{36}N_2O_5$, M= 444.56, 0.50 x 0.30 x 0.10 mm, a = 9.120(1), b = 12.047(1), c =12.252(1) Å, $\alpha = 78.17(1)$, $\beta = 80.14(1)$, $\gamma = 70.96(1)^\circ$, V =1237.5(2) Å³, $\rho_{calc} = 1.193$ g cm⁻³, $\mu = 6.69$ cm⁻¹, empirical absorption correction via φ scan data (0.953 $\leq C \leq 0.999$), Z = 2, triclinic, space group *P*1bar (No. 2), $\lambda = 1.54178$ Å, T = 223 K, $\omega/2\theta$ scans, 5387 reflections collected (+h, ±k, ±J), [(sin $\theta)/\lambda$] = 0.62 Å⁻¹, 5053 independent and 4144 observed reflections [$I \geq 2 \sigma(I)$], 295 refined parameters, R = 0.060, $wR^2 = 0.171$, max. residual electron density 0.59 (-0.36) e Å⁻³, hydrogens calculated and refined as riding atoms.
- For similar observations see: a) Faibish, N. C.; Park, Y. S.; Lee, S.; Beak, P. J. Am. Chem. Soc. 1997, 119, 11561. b) Thayumanavan, S.; Basu, A., Beak, P. J. Am. Chem. Soc. 1997, 119, 8209.
- a) Hoppe, D.; Carstens, A.; Krämer, T. Angew. Chem. 1990, 102, 1455; Angew. Chem. Int. Ed. Engl. 1990, 29, 1424. b) Derwing, C.; Hoppe, D.; Synthesis 1996, 149. c) Hammerschmidt, F.; Hanninger, A. Chem. Ber. 1995, 128, 1069. d) Gallagher, D. J.; Du, H.; Long, S. A.; Beak, P. J. Am. Chem. Soc. 1996, 118, 11391.
- 19. Little is known about the stereochemistry of the substitution in carbon-substituted benzyllithium compounds; a different reaction pattern cannot be strictly excluded.
- 20. Review: Caddick, S.; Jenkins, K. Chem. Soc. Rev. 1996, 447.